BRPI0922823A2 - Combinações e modos de administração de agentes terapêuticos e terapia de combinação - Google Patents
Combinações e modos de administração de agentes terapêuticos e terapia de combinaçãoInfo
- Publication number
- BRPI0922823A2 BRPI0922823A2 BRPI0922823-3A BRPI0922823A BRPI0922823A2 BR PI0922823 A2 BRPI0922823 A2 BR PI0922823A2 BR PI0922823 A BRPI0922823 A BR PI0922823A BR PI0922823 A2 BRPI0922823 A2 BR PI0922823A2
- Authority
- BR
- Brazil
- Prior art keywords
- administration
- modes
- combinations
- therapeutic agents
- combination therapy
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20162408P | 2008-12-11 | 2008-12-11 | |
| US17843009P | 2009-05-14 | 2009-05-14 | |
| PCT/US2009/067766 WO2010068925A1 (en) | 2008-12-11 | 2009-12-11 | Combinations and modes of administration of therapeutic agents and combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0922823A2 true BRPI0922823A2 (pt) | 2015-08-18 |
Family
ID=42243099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0922823-3A BRPI0922823A2 (pt) | 2008-12-11 | 2009-12-11 | Combinações e modos de administração de agentes terapêuticos e terapia de combinação |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20120128732A1 (pt) |
| EP (1) | EP2367425B1 (pt) |
| AU (3) | AU2009324464B2 (pt) |
| BR (1) | BRPI0922823A2 (pt) |
| CA (1) | CA2746129A1 (pt) |
| ES (1) | ES2668837T3 (pt) |
| IL (2) | IL213407A (pt) |
| MX (1) | MX2011006167A (pt) |
| NZ (1) | NZ593343A (pt) |
| WO (1) | WO2010068925A1 (pt) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| EP1585548B1 (en) | 2002-12-09 | 2018-06-27 | Abraxis BioScience, LLC | Compositions and methods of delivery of pharmacological agents |
| WO2006089290A1 (en) | 2005-02-18 | 2006-08-24 | Abraxis Bioscience Inc.. | Combinations and modes of administration of therapeutic agents and combination therapy |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| BRPI0615265A8 (pt) * | 2005-08-31 | 2018-03-06 | Abraxis Bioscience Llc | composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos |
| PT2117520T (pt) | 2006-12-14 | 2018-12-04 | Abraxis Bioscience Llc | Terapia do cancro da mama com base no estado do receptor do hormona com nanoparticulas compreendendo taxane |
| LT2481402T (lt) * | 2007-03-07 | 2018-10-25 | Abraxis Bioscience, Llc | Nanodalelė, apimanti rapamiciną ir albuminą, kaip priešvėžinį agentą |
| US20100166869A1 (en) * | 2007-05-03 | 2010-07-01 | Desai Neil P | Methods and compositions for treating pulmonary hypertension |
| AU2008260447B2 (en) * | 2007-06-01 | 2013-10-10 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| CN102460167B (zh) | 2009-04-15 | 2015-07-22 | 阿布拉科斯生物科学有限公司 | 不含朊病毒的纳米颗粒组合物和方法 |
| CN104784121A (zh) | 2010-03-26 | 2015-07-22 | 阿布拉科斯生物科学有限公司 | 治疗肝细胞癌的方法 |
| NZ602385A (en) | 2010-03-29 | 2014-08-29 | Abraxis Bioscience Llc | Methods of treating cancer |
| WO2011123393A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
| JP2013527232A (ja) * | 2010-06-02 | 2013-06-27 | アブラクシス バイオサイエンス， エルエルシー | 膀胱がんの処置方法 |
| KR20130088116A (ko) | 2010-06-04 | 2013-08-07 | 아브락시스 바이오사이언스, 엘엘씨 | 췌장암의 치료 방법 |
| MY166014A (en) * | 2010-06-07 | 2018-05-21 | Abraxis Bioscience Llc | Combination therapy methods for treating proliferative diseases |
| ES2388963B1 (es) * | 2011-03-24 | 2013-09-13 | Univ Navarra | Desarrollo y uso de nanoparticulas lipidicas conteniendo edelfosina y otros eteres de fosfolipidos en la terapia antitumoral y antiparasitaria |
| BR112013027674A2 (pt) | 2011-04-28 | 2016-09-06 | Abraxis Bioscience Llc | "usos de composições de nanopartículas, composições compreendendo as referidas nanopartículas e cateter com uma agulha". |
| PT2790675T (pt) | 2011-12-14 | 2019-09-23 | Abraxis Bioscience Llc | Utilização de excipientes poliméricos para a liofilização ou a congelação de partículas |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| WO2014087413A1 (en) * | 2012-12-03 | 2014-06-12 | Vishwa Vidya Peetham University Amrita | Nanoparticles comprising sorafenib |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| NZ630239A (en) * | 2013-02-11 | 2017-08-25 | Abraxis Bioscience Llc | Methods of treating melanoma |
| ES2804323T3 (es) | 2013-03-12 | 2021-02-05 | Abraxis Bioscience Llc | Procedimientos de tratamiento de cáncer de pulmón |
| WO2014138881A1 (en) * | 2013-03-12 | 2014-09-18 | Patheon, Inc. | Drug delivery system |
| KR20220123335A (ko) | 2013-03-13 | 2022-09-06 | 온코슈틱스 인코포레이티드 | 7-벤질-10-(2-메틸벤질)-2,6,7,8,9,10-헥사하이드로이미다조[1,2-a]피리도[4,3-d]피리미딘-5(3h)-온과의 조합 치료요법 |
| US9688679B2 (en) | 2013-03-13 | 2017-06-27 | Oncoceutics, Inc. | 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy |
| US9376437B2 (en) | 2013-03-13 | 2016-06-28 | Oncoceutics, Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy |
| CA2903548A1 (en) | 2013-03-14 | 2014-09-25 | Abraxis Bioscience, Llc | Methods of treating bladder cancer |
| JP6431528B2 (ja) * | 2013-04-10 | 2018-11-28 | マサチューセッツ インスチテュート オブ テクノロジーＭａｓｓａｃｈｕｓｅｔｔｓ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｔｅｃｈｎｏｌｏｇｙ | 癌治療のための薬物局所送達装置及び方法 |
| ES2724331T3 (es) * | 2013-11-15 | 2019-09-10 | Oncoceutics Inc | 7-Bencil-4-(2-metilbencil)-2,4,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1H)-ona, sales de la misma y procedimientos de uso |
| WO2015157120A1 (en) * | 2014-04-06 | 2015-10-15 | Abraxis Bioscience, Llc | Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer |
| MD3805222T2 (ro) | 2015-01-30 | 2025-04-30 | Oncoceutics Inc | Derivați de 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1H)-ona, sărurile acestora și utilizarea acestora în terapie |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| EP3313401B1 (en) | 2015-06-29 | 2021-10-06 | Abraxis BioScience, LLC | Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors |
| IL277402B1 (en) | 2018-03-20 | 2026-04-01 | Abraxis Bioscience Llc | Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin |
| US20210393597A1 (en) * | 2018-11-08 | 2021-12-23 | Dana-Farber Cancer Institute, Inc. | Targeting the transcription factor nf-kb with harmine |
| KR20220106758A (ko) | 2019-10-28 | 2022-07-29 | 아브락시스 바이오사이언스, 엘엘씨 | 알부민 및 라파마이신의 제약 조성물 |
| WO2022266251A1 (en) * | 2021-06-16 | 2022-12-22 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions for treatment of psoriasis |
| IL312842A (en) | 2021-11-17 | 2024-07-01 | Panther Therapeutics Inc | Implantable and biodegradable drug delivery devices and methods of using them |
| WO2024107532A1 (en) | 2022-11-17 | 2024-05-23 | PanTher Therapeutics, Inc. | Methods of treating pancreatic cancer |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| CA2369740A1 (en) | 1999-04-22 | 2000-11-02 | American Biosciences, Inc. | Long term administration of pharmacologically active agents |
| SG157952A1 (en) * | 2001-05-30 | 2010-01-29 | Univ Michigan | Small molecule antagonists of bcl-2 family proteins |
| US20040143004A1 (en) | 2002-02-26 | 2004-07-22 | Joseph Fargnoli | Metronomic dosing of taxanes |
| JP2005535688A (ja) * | 2002-07-30 | 2005-11-24 | ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗腫瘍医薬との組合せにおけるアルキルホスホコリンの使用 |
| EP1585548B1 (en) | 2002-12-09 | 2018-06-27 | Abraxis BioScience, LLC | Compositions and methods of delivery of pharmacological agents |
| US20080161251A1 (en) * | 2005-01-21 | 2008-07-03 | Astex Therapeutics Limited | Pharmaceutical Compounds |
| WO2006089290A1 (en) * | 2005-02-18 | 2006-08-24 | Abraxis Bioscience Inc.. | Combinations and modes of administration of therapeutic agents and combination therapy |
| JP2006316040A (ja) * | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| US8034765B2 (en) | 2005-08-31 | 2011-10-11 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| US20100166869A1 (en) | 2007-05-03 | 2010-07-01 | Desai Neil P | Methods and compositions for treating pulmonary hypertension |
-
2009
- 2009-12-11 NZ NZ593343A patent/NZ593343A/xx unknown
- 2009-12-11 CA CA2746129A patent/CA2746129A1/en not_active Abandoned
- 2009-12-11 WO PCT/US2009/067766 patent/WO2010068925A1/en not_active Ceased
- 2009-12-11 EP EP09832656.4A patent/EP2367425B1/en active Active
- 2009-12-11 ES ES09832656.4T patent/ES2668837T3/es active Active
- 2009-12-11 BR BRPI0922823-3A patent/BRPI0922823A2/pt not_active Application Discontinuation
- 2009-12-11 MX MX2011006167A patent/MX2011006167A/es active IP Right Grant
- 2009-12-11 US US13/133,367 patent/US20120128732A1/en not_active Abandoned
- 2009-12-11 AU AU2009324464A patent/AU2009324464B2/en active Active
-
2011
- 2011-06-06 IL IL213407A patent/IL213407A/en active IP Right Grant
-
2013
- 2013-02-28 US US13/781,489 patent/US20140072631A1/en not_active Abandoned
-
2015
- 2015-10-26 IL IL242268A patent/IL242268A0/en unknown
-
2016
- 2016-07-29 AU AU2016208420A patent/AU2016208420A1/en not_active Abandoned
-
2018
- 2018-03-02 AU AU2018201514A patent/AU2018201514B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010068925A1 (en) | 2010-06-17 |
| IL242268A0 (en) | 2015-11-30 |
| ES2668837T3 (es) | 2018-05-22 |
| IL213407A (en) | 2016-09-29 |
| AU2009324464A1 (en) | 2011-06-30 |
| AU2018201514B2 (en) | 2019-07-11 |
| EP2367425A1 (en) | 2011-09-28 |
| NZ593343A (en) | 2013-04-26 |
| US20140072631A1 (en) | 2014-03-13 |
| CA2746129A1 (en) | 2010-06-17 |
| IL213407A0 (en) | 2011-07-31 |
| AU2016208420A1 (en) | 2016-09-01 |
| US20120128732A1 (en) | 2012-05-24 |
| AU2009324464B2 (en) | 2016-05-05 |
| EP2367425B1 (en) | 2018-02-28 |
| EP2367425A4 (en) | 2012-10-31 |
| MX2011006167A (es) | 2011-07-28 |
| AU2018201514A1 (en) | 2018-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL242268A0 (en) | Combinations and forms of administration of therapeutic factors and combined treatment | |
| IL276643A (en) | Methods to increase the transfer of drugs and the effectiveness of therapeutic agents | |
| CY2014023I2 (el) | Συνδυασμοι και τροποι χορηγησης θεραπευτικων παραγοντων και θεραπεια συνδυασμου | |
| SMT201700037B (it) | Nuovi inibitori pirrolici della s-nitrosoglutatione riduttasi come agenti terapeutici | |
| IL249941A0 (en) | Spiro-oxaindole substances and medical preparations containing them | |
| CY2014006I1 (el) | Μεθοδοι θεραπευτικης αγωγης χρησιμοποιωντας γλυκοπεγκυλιωμενο g-csf | |
| ME01814B (me) | Citotoksični agensi koji sadrže nove derivate tomaimicina i njihova terapeutska primjena | |
| HUE037082T2 (hu) | Új lipidek és készítmények terápiás hatóanyagok szállítására | |
| PL3150586T3 (pl) | Modulatory farmakokinetycznych właściwości środków terapeutycznych | |
| DE602007000323D1 (de) | Abgabe von therapeutischen Vorrichtungen | |
| BRPI0821660A2 (pt) | Combinações de agentes terapêuticos para tratamento de câncer | |
| BRPI0821779A2 (pt) | tratamento terapêutico de câncer | |
| IL211293A (en) | Combination factors for the preparation of a drug for the treatment of tuberculosis | |
| BRPI0908225A2 (pt) | derivados de piridazina e seu uso como agentes terapêuticos | |
| BRPI0916931A2 (pt) | agentes terapêuticos | |
| SI2205245T1 (sl) | Terapevtska uporaba diaminofenotiazinov | |
| IL217540A (en) | Oral composition for use in oral disinfection or in treating an oral disease | |
| EP2268281A4 (en) | THIENOPYRROLES AND PYRROLOTHIAZOLES AS NEW THERAPEUTIC AGENTS | |
| ZA201105284B (en) | Visfatin therapeutic agents for the treatment of acne and other conditions | |
| DK2293846T3 (da) | Depsipeptider og deres terapeutiske anvendelse | |
| BRPI0714318A2 (pt) | Utilização de 2-benzoil-imidazopiridinas em terapêutica | |
| GB201108289D0 (en) | Therapeutic garment and method of providing therapy using the same | |
| FI8286U1 (fi) | Kunto- ja terapiaväline | |
| TH0801000600A (th) | การร่วมกันของสารบำบัดรักษาสำหรับการบำบัดโรคมะเร็ง | |
| FI20075236A0 (fi) | Diagnostisia ja terapeuttisia aineita |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A01N 43/02 , A61K 31/335 Ipc: A61K 31/337 (2006.01) |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |